Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 174

1.

The impact of legislation mandating breast density notification - Review of the evidence.

Houssami N, Lee CI.

Breast. 2018 Sep 11;42:102-112. doi: 10.1016/j.breast.2018.09.001. [Epub ahead of print] Review.

PMID:
30236594
2.

A randomized controlled trial of digital breast tomosynthesis versus digital mammography in population-based screening in Bergen: interim analysis of performance indicators from the To-Be trial.

Aase HS, Holen ÅS, Pedersen K, Houssami N, Haldorsen IS, Sebuødegård S, Hanestad B, Hofvind S.

Eur Radiol. 2018 Aug 29. doi: 10.1007/s00330-018-5690-x. [Epub ahead of print]

PMID:
30159620
3.

Effect of integrating digital breast tomosynthesis (3D-mammography) with acquired or synthetic 2D-mammography on radiologists' true-positive and false-positive detection in a population screening trial: A descriptive study.

Bernardi D, Li T, Pellegrini M, Macaskill P, Valentini M, Fantò C, Ostillio L, Houssami N.

Eur J Radiol. 2018 Sep;106:26-31. doi: 10.1016/j.ejrad.2018.07.008. Epub 2018 Jul 10.

PMID:
30150047
4.

Breast Cancer Screening Using Tomosynthesis or Mammography: A Meta-analysis of Cancer Detection and Recall.

Marinovich ML, Hunter KE, Macaskill P, Houssami N.

J Natl Cancer Inst. 2018 Sep 1;110(9):942-949. doi: 10.1093/jnci/djy121.

PMID:
30107542
5.

Screening women with a personal history of breast cancer: overview of the evidence on breast imaging surveillance.

Houssami N, Cho N.

Ultrasonography. 2018 Jun 7. doi: 10.14366/usg.18017. [Epub ahead of print]

6.

Adherence to prescribing restrictions for HER2-positive metastatic breast cancer in Australia: A national population-based observational study (2001-2016).

Daniels B, Girosi F, Tervonen H, Kiely BE, Lord SJ, Houssami N, Pearson SA.

PLoS One. 2018 Jul 26;13(7):e0198152. doi: 10.1371/journal.pone.0198152. eCollection 2018.

7.

Systematic review of agreement between tomosynthesis and pathologic tumor size for newly diagnosed breast cancer and comparison with other imaging tests.

Marinovich ML, Macaskill P, Bernardi D, Houssami N.

Expert Rev Med Devices. 2018 Jul;15(7):489-496. doi: 10.1080/17434440.2018.1491306. Epub 2018 Jul 4.

PMID:
29927337
8.

Should women aged 70-74 be invited to participate in screening mammography? A report on two Australian community juries.

Degeling C, Barratt A, Aranda S, Bell R, Doust J, Houssami N, Hersch J, Sakowsky R, Entwistle V, Carter SM.

BMJ Open. 2018 Jun 14;8(6):e021174. doi: 10.1136/bmjopen-2017-021174.

9.

Digital breast tomosynthesis (3D mammography) for breast cancer screening and for assessment of screen-recalled findings: review of the evidence.

Li T, Marinovich ML, Houssami N.

Expert Rev Anticancer Ther. 2018 Aug;18(8):785-791. doi: 10.1080/14737140.2018.1483243. Epub 2018 Jun 7.

PMID:
29847744
10.

Long-term survival in trastuzumab-treated patients with HER2-positive metastatic breast cancer: real-world outcomes and treatment patterns in a whole-of-population Australian cohort (2001-2016).

Daniels B, Kiely BE, Lord SJ, Houssami N, Lu CY, Ward RL, Pearson SA.

Breast Cancer Res Treat. 2018 May 7. doi: 10.1007/s10549-018-4804-0. [Epub ahead of print]

PMID:
29736743
11.

An exploratory radiomics analysis on digital breast tomosynthesis in women with mammographically negative dense breasts.

Tagliafico AS, Valdora F, Mariscotti G, Durando M, Nori J, La Forgia D, Rosenberg I, Caumo F, Gandolfo N, Houssami N, Calabrese M.

Breast. 2018 Aug;40:92-96. doi: 10.1016/j.breast.2018.04.016. Epub 2018 Apr 30.

PMID:
29723697
12.

Cumulative Risk Distribution for Interval Invasive Second Breast Cancers After Negative Surveillance Mammography.

Lee JM, Abraham L, Lam DL, Buist DSM, Kerlikowske K, Miglioretti DL, Houssami N, Lehman CD, Henderson LM, Hubbard RA.

J Clin Oncol. 2018 Jul 10;36(20):2070-2077. doi: 10.1200/JCO.2017.76.8267. Epub 2018 May 2.

PMID:
29718790
13.

Digital breast tomosynthesis for breast cancer screening and diagnosis in women with dense breasts - a systematic review and meta-analysis.

Phi XA, Tagliafico A, Houssami N, Greuter MJW, de Bock GH.

BMC Cancer. 2018 Apr 3;18(1):380. doi: 10.1186/s12885-018-4263-3.

14.

Comparison of breast cancers detected in the Verona screening program following transition to digital breast tomosynthesis screening with cancers detected at digital mammography screening.

Caumo F, Romanucci G, Hunter K, Zorzi M, Brunelli S, Macaskill P, Houssami N.

Breast Cancer Res Treat. 2018 Jul;170(2):391-397. doi: 10.1007/s10549-018-4756-4. Epub 2018 Mar 20.

PMID:
29557996
15.

Rapid review: radiomics and breast cancer.

Valdora F, Houssami N, Rossi F, Calabrese M, Tagliafico AS.

Breast Cancer Res Treat. 2018 Jun;169(2):217-229. doi: 10.1007/s10549-018-4675-4. Epub 2018 Feb 2. Review.

PMID:
29396665
16.

To share or not to share? Expected pros and cons of data sharing in radiological research.

Sardanelli F, Alì M, Hunink MG, Houssami N, Sconfienza LM, Di Leo G.

Eur Radiol. 2018 Jun;28(6):2328-2335. doi: 10.1007/s00330-017-5165-5. Epub 2018 Jan 18.

PMID:
29349697
17.

Interval breast cancers in the 'screening with tomosynthesis or standard mammography' (STORM) population-based trial.

Houssami N, Bernardi D, Caumo F, Brunelli S, Fantò C, Valentini M, Romanucci G, Gentilini MA, Zorzi M, Macaskill P.

Breast. 2018 Apr;38:150-153. doi: 10.1016/j.breast.2018.01.002. Epub 2018 Jan 9.

PMID:
29328943
18.

Digital Breast Tomosynthesis with Synthesized Two-Dimensional Images versus Full-Field Digital Mammography for Population Screening: Outcomes from the Verona Screening Program.

Caumo F, Zorzi M, Brunelli S, Romanucci G, Rella R, Cugola L, Bricolo P, Fedato C, Montemezzi S, Houssami N.

Radiology. 2018 Apr;287(1):37-46. doi: 10.1148/radiol.2017170745. Epub 2017 Dec 13.

PMID:
29237146
19.

Trastuzumab for metastatic breast cancer: Real world outcomes from an Australian whole-of-population cohort (2001-2016).

Daniels B, Kiely BE, Lord SJ, Houssami N, Lu CY, Ward RL, Pearson SA.

Breast. 2018 Apr;38:7-13. doi: 10.1016/j.breast.2017.11.007. Epub 2017 Nov 21.

PMID:
29172171
20.

Survival outcomes for Australian women receiving trastuzumab for HER2-positive metastatic breast cancer following (neo)adjuvant trastuzumab: a national population-based observational study (2006-2014).

Daniels B, Kiely BE, Houssami N, Lord SJ, Dobbins T, Lu CY, Ward RL, Pearson SA.

Br J Cancer. 2018 Feb 6;118(3):441-447. doi: 10.1038/bjc.2017.405. Epub 2017 Nov 14.

PMID:
29136405
21.

Evidence on Synthesized Two-dimensional Mammography Versus Digital Mammography When Using Tomosynthesis (Three-dimensional Mammography) for Population Breast Cancer Screening.

Houssami N.

Clin Breast Cancer. 2018 Aug;18(4):255-260.e1. doi: 10.1016/j.clbc.2017.09.012. Epub 2017 Sep 28. Review.

PMID:
29066138
22.

How information about overdetection changes breast cancer screening decisions: a mediation analysis within a randomised controlled trial.

Hersch J, McGeechan K, Barratt A, Jansen J, Irwig L, Jacklyn G, Houssami N, Dhillon H, McCaffery K.

BMJ Open. 2017 Oct 6;7(10):e016246. doi: 10.1136/bmjopen-2017-016246.

23.

Artificial intelligence for breast cancer screening: Opportunity or hype?

Houssami N, Lee CI, Buist DSM, Tao D.

Breast. 2017 Dec;36:31-33. doi: 10.1016/j.breast.2017.09.003. Epub 2017 Sep 20.

PMID:
28938172
24.

Accuracy of screening women at familial risk of breast cancer without a known gene mutation: Individual patient data meta-analysis.

Phi XA, Houssami N, Hooning MJ, Riedl CC, Leach MO, Sardanelli F, Warner E, Trop I, Saadatmand S, Tilanus-Linthorst MMA, Helbich TH, van den Heuvel ER, de Koning HJ, Obdeijn IM, de Bock GH.

Eur J Cancer. 2017 Nov;85:31-38. doi: 10.1016/j.ejca.2017.07.055. Review.

PMID:
28886475
25.

Carcinoma in situ of the breast in New South Wales, Australia: Current status and trends over the last 40 year.

Jacklyn G, Morrell S, McGeechan K, Houssami N, Irwig L, Pathmanathan N, Barratt A.

Breast. 2018 Feb;37:170-178. doi: 10.1016/j.breast.2017.08.005. Epub 2017 Sep 5.

PMID:
28882419
26.

Trends in stage-specific breast cancer incidence in New South Wales, Australia: insights into the effects of 25 years of screening mammography.

Jacklyn G, McGeechan K, Irwig L, Houssami N, Morrell S, Bell K, Barratt A.

Breast Cancer Res Treat. 2017 Dec;166(3):843-854. doi: 10.1007/s10549-017-4443-x. Epub 2017 Aug 19.

PMID:
28822001
27.

Comparison of synthetic mammography, reconstructed from digital breast tomosynthesis, and digital mammography: evaluation of lesion conspicuity and BI-RADS assessment categories.

Mariscotti G, Durando M, Houssami N, Fasciano M, Tagliafico A, Bosco D, Casella C, Bogetti C, Bergamasco L, Fonio P, Gandini G.

Breast Cancer Res Treat. 2017 Dec;166(3):765-773. doi: 10.1007/s10549-017-4458-3. Epub 2017 Aug 17.

PMID:
28819781
28.

Impact of extending screening mammography to older women: Information to support informed choices.

Jacklyn G, Howard K, Irwig L, Houssami N, Hersch J, Barratt A.

Int J Cancer. 2017 Oct 15;141(8):1540-1550. doi: 10.1002/ijc.30858. Epub 2017 Jul 10. Erratum in: Int J Cancer. 2017 Dec 15;141(12 ):E8.

PMID:
28662267
29.

The epidemiology, radiology and biological characteristics of interval breast cancers in population mammography screening.

Houssami N, Hunter K.

NPJ Breast Cancer. 2017 Apr 13;3:12. doi: 10.1038/s41523-017-0014-x. eCollection 2017.

30.

Accuracy and reading time for six strategies using digital breast tomosynthesis in women with mammographically negative dense breasts.

Tagliafico AS, Calabrese M, Bignotti B, Signori A, Fisci E, Rossi F, Valdora F, Houssami N.

Eur Radiol. 2017 Dec;27(12):5179-5184. doi: 10.1007/s00330-017-4918-5. Epub 2017 Jun 22.

PMID:
28643094
31.

Meta-analysis of pre-operative magnetic resonance imaging (MRI) and surgical treatment for breast cancer.

Houssami N, Turner RM, Morrow M.

Breast Cancer Res Treat. 2017 Sep;165(2):273-283. doi: 10.1007/s10549-017-4324-3. Epub 2017 Jun 6. Review.

32.

Overdiagnosis of breast cancer in population screening: does it make breast screening worthless?

Houssami N.

Cancer Biol Med. 2017 Feb;14(1):1-8. doi: 10.20892/j.issn.2095-3941.2016.0050.

33.

Breast cancer detection using single-reading of breast tomosynthesis (3D-mammography) compared to double-reading of 2D-mammography: Evidence from a population-based trial.

Houssami N, Bernardi D, Pellegrini M, Valentini M, Fantò C, Ostillio L, Tuttobene P, Luparia A, Macaskill P.

Cancer Epidemiol. 2017 Apr;47:94-99. doi: 10.1016/j.canep.2017.01.008. Epub 2017 Feb 11.

PMID:
28192742
34.

Use and outcomes of targeted therapies in early and metastatic HER2-positive breast cancer in Australia: protocol detailing observations in a whole of population cohort.

Daniels B, Lord SJ, Kiely BE, Houssami N, Haywood P, Lu CY, Ward RL, Pearson SA; HER2 therapy observational study (HER2-OBS) investigators.

BMJ Open. 2017 Jan 24;7(1):e014439. doi: 10.1136/bmjopen-2016-014439.

35.

Breast cancers detected in only one of two arms of a tomosynthesis (3D-mammography) population screening trial (STORM-2).

Bernardi D, Houssami N.

Breast. 2017 Apr;32:98-101. doi: 10.1016/j.breast.2017.01.005. Epub 2017 Jan 18.

PMID:
28107735
36.

Imaging Surveillance After Primary Breast Cancer Treatment.

Lam DL, Houssami N, Lee JM.

AJR Am J Roentgenol. 2017 Mar;208(3):676-686. doi: 10.2214/AJR.16.16300. Epub 2017 Jan 11. Review.

37.

Radiological clinical trials: Proposal of a problem-finding questionnaire to improve study success.

Valdora F, Bignotti B, Calabrese M, Houssami N, Tagliafico A.

World J Methodol. 2016 Dec 26;6(4):214-219. doi: 10.5662/wjm.v6.i4.214. eCollection 2016 Dec 26.

38.

Rapid review: Estimates of incremental breast cancer detection from tomosynthesis (3D-mammography) screening in women with dense breasts.

Houssami N, Turner RM.

Breast. 2016 Dec;30:141-145. doi: 10.1016/j.breast.2016.09.008. Epub 2016 Oct 7. Review.

PMID:
27721194
39.

Discussing the benefits and harms of screening mammography.

Brennan M, Houssami N.

Maturitas. 2016 Oct;92:150-153. doi: 10.1016/j.maturitas.2016.08.003. Epub 2016 Aug 11. Review.

PMID:
27621253
40.

Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma in Situ.

Morrow M, Van Zee KJ, Solin LJ, Houssami N, Chavez-MacGregor M, Harris JR, Horton J, Hwang S, Johnson PL, Marinovich ML, Schnitt SJ, Wapnir I, Moran MS.

Pract Radiat Oncol. 2016 Sep-Oct;6(5):287-295. doi: 10.1016/j.prro.2016.06.011. Epub 2016 Jun 24.

41.

Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma In Situ.

Morrow M, Van Zee KJ, Solin LJ, Houssami N, Chavez-MacGregor M, Harris JR, Horton J, Hwang S, Johnson PL, Marinovich ML, Schnitt SJ, Wapnir I, Moran MS.

J Clin Oncol. 2016 Nov 20;34(33):4040-4046. doi: 10.1200/JCO.2016.68.3573. Epub 2016 Oct 31.

42.

The Association of Surgical Margins and Local Recurrence in Women with Ductal Carcinoma In Situ Treated with Breast-Conserving Therapy: A Meta-Analysis.

Marinovich ML, Azizi L, Macaskill P, Irwig L, Morrow M, Solin LJ, Houssami N.

Ann Surg Oncol. 2016 Nov;23(12):3811-3821. Epub 2016 Aug 15. Review.

43.

Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery with Whole-Breast Irradiation in Ductal Carcinoma In Situ.

Morrow M, Van Zee KJ, Solin LJ, Houssami N, Chavez-MacGregor M, Harris JR, Horton J, Hwang S, Johnson PL, Marinovich ML, Schnitt SJ, Wapnir I, Moran MS.

Ann Surg Oncol. 2016 Nov;23(12):3801-3810. Epub 2016 Aug 15. Review.

44.

Breast cancer screening with tomosynthesis (3D mammography) with acquired or synthetic 2D mammography compared with 2D mammography alone (STORM-2): a population-based prospective study.

Bernardi D, Macaskill P, Pellegrini M, Valentini M, Fantò C, Ostillio L, Tuttobene P, Luparia A, Houssami N.

Lancet Oncol. 2016 Aug;17(8):1105-1113. doi: 10.1016/S1470-2045(16)30101-2. Epub 2016 Jun 23.

PMID:
27345635
45.

Diagnostic performance of contrast-enhanced spectral mammography: Systematic review and meta-analysis.

Tagliafico AS, Bignotti B, Rossi F, Signori A, Sormani MP, Valdora F, Calabrese M, Houssami N.

Breast. 2016 Aug;28:13-9. doi: 10.1016/j.breast.2016.04.008. Epub 2016 May 7. Review.

PMID:
27161411
46.

Digital breast tomosynthesis (3D-mammography) for screening women with dense breasts.

Houssami N.

Expert Rev Med Devices. 2016 Jun;13(6):515-7. doi: 10.1080/17434440.2016.1184971. Epub 2016 May 13. No abstract available.

PMID:
27133355
47.

Digital breast tomosynthesis (3D-mammography) screening: A pictorial review of screen-detected cancers and false recalls attributed to tomosynthesis in prospective screening trials.

Houssami N, Lång K, Bernardi D, Tagliafico A, Zackrisson S, Skaane P.

Breast. 2016 Apr;26:119-34. doi: 10.1016/j.breast.2016.01.007. Epub 2016 Feb 18. Review.

PMID:
27017251
48.

Adjunct Screening With Tomosynthesis or Ultrasound in Women With Mammography-Negative Dense Breasts: Interim Report of a Prospective Comparative Trial.

Tagliafico AS, Calabrese M, Mariscotti G, Durando M, Tosto S, Monetti F, Airaldi S, Bignotti B, Nori J, Bagni A, Signori A, Sormani MP, Houssami N.

J Clin Oncol. 2016 Mar 9. pii: JCO634147. [Epub ahead of print]

PMID:
26962097
49.

Contribution of mammography to MRI screening in BRCA mutation carriers by BRCA status and age: individual patient data meta-analysis.

Phi XA, Saadatmand S, De Bock GH, Warner E, Sardanelli F, Leach MO, Riedl CC, Trop I, Hooning MJ, Mandel R, Santoro F, Kwan-Lim G, Helbich TH, Tilanus-Linthorst MM, van den Heuvel ER, Houssami N.

Br J Cancer. 2016 Mar 15;114(6):631-7. doi: 10.1038/bjc.2016.32. Epub 2016 Feb 23.

50.

Digital Breast Tomosynthesis: A Brave New World of Mammography Screening.

Houssami N, Miglioretti DL.

JAMA Oncol. 2016 Jun 1;2(6):725-7. doi: 10.1001/jamaoncol.2015.5569. No abstract available. Erratum in: JAMA Oncol. 2016 Jun 1;2(6):833.

PMID:
26892954

Supplemental Content

Loading ...
Support Center